2024
Second‐line immunotherapy in new onset refractory status epilepticus
Hanin A, Muscal E, Hirsch L. Second‐line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024, 65: 1203-1223. PMID: 38430119, DOI: 10.1111/epi.17933.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeSecond-line immunotherapyOnset refractory status epilepticusRefractory status epilepticusIntrathecal dexamethasoneStatus epilepticusCytokine levelsFunctional outcomesCerebrospinal fluid cytokine levelsInitiation of anakinraReduction of seizure frequencyLong-term functional outcomeResponse to treatmentSE onsetElevated serumFebrile infectionsImmune dysregulationLong-term disabilityTreatment initiationCase reportCytokine measurementsProspective studyAnakinraImmunotherapyTocilizumab
2004
The hazards of lack of co-registration of ictal brain SPECT with MRI: A case report of sinusitis mimicking a brainstem seizure focus
Butler T, Hirsch LJ, Claassen J. The hazards of lack of co-registration of ictal brain SPECT with MRI: A case report of sinusitis mimicking a brainstem seizure focus. BMC Medical Physics 2004, 4: 2. PMID: 15569392, PMCID: PMC535895, DOI: 10.1186/1471-2385-4-2.Peer-Reviewed Original ResearchSeizure-like episodesSeizure focusBrain SPECTBackgroundSingle photon emissionIctal brain SPECTIctal SPECT studiesSeizure-free periodInterictal studiesInjection of radiotracerRefractory seizuresIctal SPECTCase reportSphenoid sinusRadiotracer uptakeHigh-resolution structural imagesSPECT studiesYoung womenSPECTFocal areasSeizuresPhoton emissionMRIEpisodesSinusitisEncephalitis